Navigation Links
R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
Date:10/24/2007

, safety, tolerability and food effect of R7128 in healthy volunteers and in patients chronically infected with HCV genotype 1. This adaptive Phase 1 study is comprised of three parts:

Part 1 is a single ascending dose study of R7128 conducted in 46 healthy volunteers. The primary objective of Part 1 is to assess the safety, tolerability and pharmacokinetics of R7128 following single ascending doses under fasting conditions. The secondary objective of Part 1 is to explore the effect of food on the pharmacokinetics of R7128. Results from the single ascending dose portion of the study indicated that all doses of R7128 studied (500 mg to 9000 mg) were generally safe and well-tolerated. All patients completed the study, and none experienced gastrointestinal adverse events or serious adverse events during the study. No hematological or laboratory abnormalities of clinical significance were noted.

Part 2 is a multiple ascending dose study of R7128 conducted in 40 patients chronically-infected with HCV genotype 1 who previously failed interferon therapy. The primary objective of Part 2 is to assess the safety, tolerability and pharmacokinetics of R7128 after once-daily (QD) or twice- daily (BID) dosing for 14 days. The secondary objective is to assess antiviral activity by measuring the change in HCV RNA. Preliminary data from the multiple ascending dose portion of the study indicated that R7128 demonstrated potent, dose-dependent antiviral activity in four patient cohorts receiving 750 mg or 1500 mg administered either once-daily or twice-daily for 14 days as monotherapy. Patients receiving 1500 mg BID demonstrated a mean 2.7 log10 IU/mL (>99%) decrease in HCV RNA. There was no evidence of viral rebound in any dose cohort during the 14 days of dosing. R7128 was generally safe and well tolerated. There were no serious adverse events, no adverse events requiring dose modification, no dose-related gastrointestinal adverse events and no clinically significant chan
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
4. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
5. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Stanford Researchers Track Human Stem Cells Transplanted Into Rat Brain
8. Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
9. Staphylococcus aureus vaccine development on track ? safe and immunogenic in Phase I clinicaltrials
10. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
11. Point of Care Strep Tests Speed Treatment, Lower Costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)...  Uroplasty, Inc. (NASDAQ: UPI ), a medical ... products to treat voiding dysfunctions, today announced that it ... Tuesday, March 10, 2015. Rob Kill , President ... Officer, will present at 4:00 p.m. Pacific Time and ... at the Ritz Carlton in Laguna Niguel, ...
(Date:2/27/2015)... 27, 2015  Two mass spectrometry technologies ... as their effectiveness is established, according to ... Information says that while mass spectrometry (mass ... tool in proteomic biomarker discovery and validation, ... traditional techniques has struggled to elucidate molecular ...
(Date:2/26/2015)... , Feb. 26, 2015  Tandem Diabetes Care®, Inc. ... and manufacturer of the t:slim® and t:flex™ Insulin Pumps, ... of 5,250,000 shares of its common stock at a ... net proceeds to Tandem from this offering are expected ... commissions and other estimated offering expenses payable by Tandem. ...
Breaking Medicine Technology:Uroplasty to Participate in the 27th Annual ROTH Conference 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3
... LONDON, March 2, 2012  ConvaTec, a world-leading developer ... and hospital care today announced that Amcare Ltd, ... has acquired SureCalm Healthcare Holdings Ltd and subsidiaries ... specialises in the home delivery of prescribable stoma ...
... Mich., March 2, 2012 Rubicon Genomics, Inc., ... to improve the capabilities and performance of DNA ... has selected Velesco Pharmaceutical Services to manufacture the ... with Agendia,s breast cancer diagnostics.  Velesco is a ...
Cached Medicine Technology:ConvaTec Announces Acquisition of SureCalm Healthcare 2Rubicon Genomics Selects Velesco to Manufacture its TransPLEX® RNA Amplification Kits for Clinical Diagnostic Use 2Rubicon Genomics Selects Velesco to Manufacture its TransPLEX® RNA Amplification Kits for Clinical Diagnostic Use 3
(Date:2/28/2015)... (PRWEB) February 28, 2015 A study ... promising new gene therapy procedure for the treatment of ... in patients. Authored by Dr. Robert MacLaren, ... published in the Lancet Medical Journal on January 16, ... choroideremia, a rare genetic disorder that mostly affects men ...
(Date:2/28/2015)... February 28, 2015 Pioneer Millworks reclaimed ... Japan Architecture & Construction Materials Show, an annual, premier ... than 1,000 suppliers and top manufacturers of the latest ... wood products sourced and manufactured by Pioneer Millworks ... popularity in Japan at restaurants, hotels, retailers, and corporate ...
(Date:2/28/2015)... India Network Foundation, a US ... programs for visitors coming to the United States for ... to the United States are suffering from one or ... These diseases are so common among the elderly population ... conditions. There were 66.8 million cases of diabetes in ...
(Date:2/28/2015)... How would you describe your leadership ... all kinds of different leaders, each with their ... advantages and applications of different leadership styles, Ohio-based ... product this spring called The Leadership Report that ... personality type, leadership, and success. The Leadership Report ...
(Date:2/28/2015)... Toronto, ON (PRWEB) February 28, 2015 ... the Art of Facial Surgery was recently featured in ... 82 of the magazine, Dr. David Ellis was featured ... He discussed the various cosmetic enhancements that Kim Cattrall ... skin. , “Her forehead is smooth without horizontal ...
Breaking Medicine News(10 mins):Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 2Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 3Health News:PeopleKeys Launches The Leadership Report 2Health News:PeopleKeys Launches The Leadership Report 3Health News:Dr. David Ellis Featured In Elevate Magazine 2
... Function Drinks,announced today the launch of their ... on supporting sexual health. Function: Night Life ... amino acid, tyrosine, to provide,the building blocks ... with reward and desire. Epimedium, niacin and,cnidium ...
... for ... consumers, PRINCETON, N.J., June ... care products,announced today that its key product line, MEDIHONEY(TM) Wound & Burn,Dressings ... counter (OTC) sales. This will provide consumers with expanded,access to the products ...
... Kiner has,been named vice president and general manager ... In this new role, Stewart is responsible for,providing ... senior market lines of business, including Medicare Advantage ... Kiner will report to,Karen Vigil, senior vice president ...
... 24 Speaker Nancy Pelosi,issued the following statement ... Act, which passed the House this afternoon by ... bipartisan and veto-proof vote sends a strong signal ... for providers will not,be held hostage to the ...
... Zuccari,President & CEO of Hamilton Insurance Agency is featured ... Health Care Association this,June for his recent work with ... by the AHCA," said Alan J. Zuccari. "I,am proud ... focus is providing quality care.", Below is the ...
... supply, study suggests , , TUESDAY, June 24 (HealthDay News) ... help reduce a form of brain injury that affects ... study. , Hypoxic-ischemia, a compromise of the brain,s ... and cognitive/behavioral problems. , In experiments with rats that ...
Cached Medicine News:Health News:Function Drinks Launches New Product to Support Sexual Health 2Health News:Derma Sciences Receives FDA Clearance to Sell MEDIHONEY(TM) Over the Counter 2Health News:Derma Sciences Receives FDA Clearance to Sell MEDIHONEY(TM) Over the Counter 3Health News:Blue Shield of California Appoints Industry Veteran as New Vice President and General Manager for Senior Market 2Health News:Alan J. Zuccari Featured by the American Health Care Association as a June PAC Member 2Health News:Alzheimer's Drug May Reduce Preemie Brain Injury 2
... a centimeter ruler etched into the gel tray ... includes apparatus, connecting cables, three 7x10 cm gel ... three 14-well combs. The Chameleon can accomodate up ... of a maximum of 120 samples with a ...
... of a Separation-Control unit for system control ... gel staining. The optional PhastTransfer Kit quickly ... unit. Electrophoresis is performed on a thermostatic ... 0 to +70 C. Multi-step programming capability ...
... The SEA 2000 apparatus and ready-to-use gels ... for analysis of nucleic acids by submerged ... complete this system, offering full compatibility and ... Besides the SEA 2000 and a unique ...
... SEA 2000 apparatus and ready-to-use gels are ... analysis of nucleic acids by submerged gel ... this system, offering full compatibility and optimal ... the SEA 2000 and a unique staining ...
Medicine Products: